

INDEX

- ACE inhibitors, *see also* Angiotensin converting enzyme
 angiotensin (1–7) and, 233
 cardiac overload and, 23, 60
 myocardial fibrosis and, 61
 myocardial infarction and, 23, 30
- Acholeplasma laidlawii, 238–239
- ACTH, 9, 105, 109, 112
- Adenylate cyclase
 AT₁ receptors and, 11, 40, 123, 217
 AT₂ receptors and, 148
- Adipose tissue, AT₁ receptors in, 39–47
- Adrenal glands
 AT₁ receptors in
 antagonists, 135, 136
 antisense injections and, 89
 with hypertension, 49–58
 subtypes, 8, 9, 61
 hypothalamic AT₁ receptors and, 110–111
- Adrenal glomerulosa cells, desensitization in, 65
- Adrenergic neurons, 94, 96
- Aggregation of receptors, 65–66
- Aldosterone, 20, 56, 60
- Amphibian receptors, 239–240, 242
- Angiogenesis
 AT₂ receptors and, 172
 avian receptors and, 240
- Angiotensin I, 45, 238
- Angiotensin II, *see also* Renin-angiotensin system
 behavioural effects, 96, 98
 in carbohydrate-induced hypertension, 49–58
 cardiovascular effects, 59–60, 226–227, 237
 drinking response, 86, 94–96, 97–98, 113–119
 fluid balance effects, 11, 199
 growth promoting effects, 219
 hypothalamic-pituitary-adrenal effects, 105–106
 as a neurotransmitter, 113
 peptide analogues, 134–141
 tissues expressed in, 1
- Angiotensin III
 brain activity, 114
 receptor affinities for, 45, 238, 253
- Angiotensin IV, 233, 242, 250, 253–263
- Angiotensin (1–7), 242–243
 kidney binding, 231
 medulla oblongata activity, 225–235
- Angiotensin (2–8), *see* Angiotensin III
- Angiotensin (3–7), 233
- Angiotensin (3–8), 233, 242, 250, 253–263
- Angiotensin (4–8), 260
- Angiotensin converting enzyme, *see also* ACE inhibitors
 in cardiac hypertrophy, 23
 substrates for, 199
- Angiotensin receptors, *see* AT₁ receptors; AT₂ receptors; Atypical receptors
- Angiotensinogen, 199; *See also* Renin-angiotensin system
 in adipose tissue, 40
 antisense oligonucleotide for, 82, 84, 85–86
 in brain, 121, 127
 in heart, 23, 60
 hypertension and, 85–86, 90
 regulation by angiotensin II, 127
- Antagonists
 of AT₁ receptor, 131–143, 237–238
 of AT₂ receptor, 237–238
- Antisense oligonucleotides
 for angiotensinogen, 82, 84, 85–86
 for AT₁ receptor, 82, 85–89
 controls, 89
 designing of, 79–82
 effectiveness, 84–85
 for inhibiting hypertension, 79, 85–90
 mechanisms of action, 81, 83–84
 specificity, 84
 stability, 83
 viral vectors, 89–90
- Aorta, AT₁ receptors in
 for assay of angiotensin analogues, 136–137
 with carbohydrate-induced hypertension, 49–58
- AP-1 binding sequences
 of AT₁ gene, 46
 of AT₂ gene, 151, 222

- Apoptosis, AT₂ receptors and
 in ovary, 176, 180–181
 in vascular smooth muscle, 219
- Arachidonic acid, 149
- Astrocytes, *see also* Glial cells
 angiotensin II receptors in, 121–129
 angiotensin (3–8) receptors in, 254–262
 angiotensin (1–7)-stimulated prostaglandin release, 243
- AT₁ receptors
 in adipose tissue, 39–47
 amino acid sequence, 146
 antagonists, 131–143, 237–238
 antisense oligonucleotide for, 82, 85–89
 of astrocytes, 121–129
 brain distribution, 9, 93–94
 with carbohydrate-induced hypertension, 49–58
 catecholamine neurons and, 94, 99–100
 desensitization, 63–66
 gene regulation
 after myocardial infarction, 23–32
 cis-regulatory elements, 1–10, 46
 human, 18–20
 in spontaneously hypertensive rats, 71–78
 with STAT proteins, 62–63
 genome organization, 14–18
 of glial cells, 1–10, 108
 in heart, 59–69
 after myocardial infarction, 23–32
 with hypertension, 49–58
 heterogeneity
 human, 12, 14–16, 20
 rat (*see* AT_{1a} receptors; AT_{1b} receptors)
 human, 11–21
 in hypothalamus, 49–58, 88, 93, 106–108
 internalization, 66–67
 of intestinal epithelial cells, 241
 in kidney, 33–37
 in medulla oblongata, 94, 230–232
 of neuroblastoma cells, 200
 of ovarian granulosa cells, 178
 signal transduction pathways, 11, 40, 59–60, 62–66, 67, 217
 in astrocytes, 123, 125, 126
c-fos in, 76
 sodium intake and, 33–37
 in subfornical organ, 113, 116
 tissue distribution, 8–9, 15
- AT_{1a} receptors, 11–12
 amino acid sequence, 146
 in brain, 37, 88
 desensitization, 63–66
 gene regulation
 after myocardial infarction, 24, 26, 28, 30–31
 cis-regulatory elements, 1–10
 in heart, 59–69
 internalization, 66–67
 in kidney, 33–37
 signal transduction pathways, 62–66, 67
 tissue distribution, 8
- AT_{1b} receptors, 11–12
 in adrenal gland, 8, 9, 61
 in brain, 37, 88
 gene regulation
 after myocardial infarction, 24, 26, 28, 30–31
 promoter sequence, 9
 in heart, 60
 in kidney, 33–37
 in pituitary, 9
 signal transduction pathways, 66, 67
 tissue distribution, 8–9
- AT₂ receptors
 amino acid sequence, 158
 angiotensin III binding, 45
 angiotensin (1–7) binding, 232, 233
 antagonists, 237–238
 of astrocytes, 123–125, 127–128
 brain distribution, 93, 94
 cloning of, 205–206, 218
 human, 153–158
 in development, 40, 61, 153, 171–172, 189
 of brain, 127, 128, 153, 247
 of kidney, 163–164, 191
 in drinking response, 116–117
 gene cloning, 145–146, 162–163, 168–169
 gene regulation, 150–151, 222–223
 after myocardial infarction, 24, 26–31
 human, 163
 in growth, 40, 61, 171–172
 of vascular smooth muscle, 149, 172, 218–222, 237
 in heart, 60–61
 hemodynamic effects, 149, 247
 heterogeneity, 172
 in murine neuroblastoma cells, 149, 200–208
 in rat brain, 172, 247
 in rat kidney and fetus, 189–197
 homology with AT_{1a}, 23–24
 human, 153–165
 in hypothalamus, 148, 203
 internalization not observed, 66
 in medulla oblongata, 230–232
 of neuroblastoma cells, 149, 167–173, 199–208
 in neuronal function, 40
 in ovaries, 183–187
 granulosa cells, 175–182, 183–184
 signal transduction pathways, 61, 148–149, 155, 209–215, 217, 221–222
 structure, 147, 170
 tissue distribution, 31, 149–150, 153, 161–162, 163, 175, 189, 217
- AT₃ receptors, 241
- AT₄ receptors, 242; *See also* Angiotensin (3–8)
- Atypical receptors, 134, 237–245
 avian, 131, 240
 for fragments of angiotensin II, 233, 242–243, 253–263
 in gerbil brain, 247–252
 mammalian, 240–242
 of *Mycoplasma*, 238–239
 of *Xenopus*, 239–240

- Avian receptors, 131, 240
- Baroreceptor reflexes, 225–227, 228, 232
drinking response and, 117
- Biphenylimidazole antagonists, 237
- Blood vessels
cerebral
 angiotensin (3–8) and, 242
 AT₂ receptors in, 247, 248
 endothelial cell receptors in, 121
 repair of, 149, 172, 219–222, 237
- Bp3*, 218
- Brain
 angiotensin (3–8) receptors, 242, 253–263
 AT₁ receptors
 of astrocytes, 121–129
 catecholamines and, 94, 99–100
 distribution, 9, 93–94
 gene regulation, 7
 of glial cells, 1–10, 108
 hypertension and, 71–78
 in hypothalamus, 49–58, 88, 93, 106–112
 in medulla oblongata, 230–232
 of neuroblastoma cells, 200
 sodium intake and, 37
 in subfornical organ, 113, 116
 AT₂ receptors
 of astrocytes, 123–125, 127–128
 in cerebellum, 203, 251
 in cerebral arteries, 248
 in development, 127, 128, 153, 247
 distribution, 93, 94, 202–203
 heterogeneity, 149, 172, 200–208, 247
 in hypothalamus, 148, 203
 in medulla oblongata, 230–232
 of neuroblastoma cells, 149, 167–173, 199–208
 PP2A coupling to, 209–215
 atypical receptors of gerbil, 247–252
 drinking response and, 113–119
 renin-angiotensin system in, 121
 catecholamines and, 93–103
 glucocorticoids and, 111
 hypertension and, 71, 75–76, 85–86, 121
 pineal, 96
- Brainstem, PP2A activity in, 209–210; *See also*
 Cerebellum; Medulla oblongata
- Calcium, intracellular, *see also* Phosphoinositide/calcium pathway
 desensitization of transients, 63, 64
 Xenopus receptors and, 239
- Calcium channels, 11, 148, 155, 181
- Carbohydrate-induced hypertension, 49–58
- Cardiac angiotensin receptors, 59–69
- Cardiac growth, 59–60
- Cardiac hypertrophy, 60, 61
 angiotensin IV and, 262
 gene regulation in, 23–24, 30–31
 with hypertension, 49, 53, 55–57
- Cardiac renin-angiotensin system, 23, 60
- Catecholamines
 avian angiotensin receptors and, 240
 in brain, 93–103, 107–108
 in brown adipose tissue, 40
 drinking response and, 94–96, 97–98, 117
 plasma levels during stress, 110
- Cerebellum
 angiotensin (3–8) receptors, 253–254
 AT₁ receptors, on astrocytes, 124–125, 127
 AT₂ receptors, 203, 251
- Cerebral cortex, AT₁ receptors in, 124, 126, 127
- CGP42112A, 189, 237
- Chicken receptors, 240
- Cis-regulatory elements
 of human AT_{1a} receptor gene, 9
 of mouse AT₂ receptor gene, 151
 of rat AT_{1a} receptor gene, 1–10
- Clathrin-coated pits, 66
- Constitutive receptor activity, 132–134
- Corpus luteum, 185–186
- Corticotropin releasing hormone, 105, 106, 107, 108, 110, 111
- Cyclic AMP, *see* Adenylate cyclase
- Cyclic GMP
 angiotensin (3–8) receptors and, 242
 AT₂ receptors and, 148, 238
 atypical neuroblastoma receptors and, 240–241
- Cytokines, STAT proteins and, 62–63
- Desensitization of receptors, 63–66
- Development, *see* AT₂ receptors, in development
- Diacylglycerol, 62
- Dimerization of receptors, 65–66
- Dithiothreitol
 AT₁ vs. AT₂ binding and, 178, 238
 AT₂ subtypes binding and, 204
- DOCA-salt model, 76
- Dopamine, 94, 97–101, 107
- Drinking response
 antisense inhibition of, 86
 brain regions involved in, 113–115
 catecholamines and, 94–96, 97–98
 cholinergic mechanisms, 114
 fluid intake and, 115–116
 hypotension and, 117
 hypovolemia and, 117–118
 osmotic stimuli, 116
 receptor types in, 116–117
 sodium appetite and, 117–118
- DuP753, *see* Losartan
- Endocytosis of receptors, 66–67
- Estrogen, 186
- EXP3174, 65
- FAK¹²⁵, 62

- Fibroblasts
 AT_{1a} receptors in, 24, 30, 61–62
 AT₂ receptors in, 150, 222–223
 signal transduction in, 62
- Fluid balance, *see* Drinking response; Osmotic stimuli
- Focal adhesion proteins, 62
- Follicle stimulating hormone (FSH), 176, 178–181, 185
- c-fos*, angiotensin induction of, 61, 62
 in spontaneously hypertensive rats, 71–78
- Fos immunoreactivity, 113, 114
- Fructose, hypertension and, 49–58
- G proteins
 AT₁ receptors and, 11, 61, 63, 64, 217, 238
 AT₂ receptors and, 148, 217, 238
 with PP2A, 209–210, 212–213
 with PTPase, 31, 61, 155
 with receptor subtypes, 204
 desensitization of receptors and, 63
- Gene regulation, *see* Transcription factors
- Gene transfer *in vivo*, 218–220
- Glial cells, *see also* Astrocytes
 angiotensin (3–8) receptors in, 254–262
 AT₁ receptors in, 1–10, 108
- Glial fibrillary acidic protein (GFAP), 121
- Glucocorticoids
 AT_{1a} gene expression and, 30
 hypothalamic AT₁ receptors and, 108, 110–111, 112
- Growth
 AT₁ receptors and, 164
 AT₂ receptors and, 40, 61, 164, 171–172
 cardiac, 59–60
 of vascular smooth muscle, 149, 172, 218–222
- Growth factors
 in cardiac hypertrophy, 61
 in ovarian apoptosis, 180–181
 STAT proteins and, 62–63
- Growth hormone, 107
- Guanylate cyclase, angiotensin (3–8) receptors and, 242
- Heart failure, 60
- Hemagglutinating Virus of Japan (HVJ), 219
- High mobility group 1 protein (HMG-1), 219
- Hippocampus
 angiotensin (3–8) receptors in, 253
 atypical gerbil receptors in, 248–251
- Hyperinsulinemia, hypertension and, 49–58
- Hypertension
 angiotensin (1–7) and, 233
 animal models, 72, 76
 antisense oligonucleotides for, 79, 85–90
 carbohydrate-induced, 49–58
 spontaneously hypertensive rats, 71–78, 115, 218
- Hypertrophic marker genes, 61
- Hypertrophy, *see* Cardiac hypertrophy
- Hypothalamic-pituitary-adrenal axis, 105–112
- Hypothalamic-thalamus-septum, 76
- Hypothalamus
 angiotensin (1–7) in, 227–228, 232–233
 antisense treatment and, 87–89
 astrocytes in, 124, 126, 127
 AT₁ receptors in, 88, 93, 106–108
 with hypertension, 49–58, 73
 AT₂ receptors in, 148, 203
 dopamine in, 97, 99–100
 in drinking response, 96, 113–118
 noradrenaline in, 96–97
 PP2A activity in, 209–210
 in stress response, 105–112
- Immediate-early genes, 61
- Inferior olive, 203, 206, 251
- Inositol triphosphate, *see* Phosphoinositide/calcium pathway
- Insulin
 AT₂ gene expression and, 151
 with carbohydrate-enriched diet, 49–58
- Interleukin-1 β , 151
- Internalization
 of AT₁ receptors, 66–67
 of AT₂ receptors, 66, 148
- Intestinal epithelium, atypical receptors in, 241
- Intrinsic receptor activity, 132–134
- Inverse agonist, 131–134
- IRF proteins, 222
- Kidney
 AT₁ receptors in, 33–37
 AT₂ receptors in, 163–164, 190–196
- Locus coeruleus, 203, 206
- Losartan (DuP753)
 binding locus, 134
 brain penetration, 117
 receptor internalization and, 66
 specificity, 116, 237
- Luteinizing hormone, 184
- Macrophage receptors, 251
- MAP kinase
 AT_{1a} receptors and, 62, 65
 AT₂ receptors and, 221–222
 PP2A and, 215
- mas* oncoprotein, 241–242
- Medulla oblongata
 angiotensin (1–7) activity in, 227–235, 243
 astrocytes in, 124–125, 126, 127
 AT₁ receptors in, 73, 94, 230–232
- c-myc*, 223
- Mycoplasma
 binding sites on, 238–239
 contamination from, 239, 241
- Myocardial fibrosis, 61

- Myocardial infarction, 23–32, 60, 61
- Myocytes, cardiac
hypertrophy, 60, 61
receptor subtypes in, 23–24, 30–31
signal transduction in, 62
- Neointimal proliferation, 149, 172, 219–222, 237
- Nerve growth factor, 150
- Neuroblastoma cells
AT₁ receptors in, 200
AT₂ receptors in, 149, 167–173, 199–208
atypical receptors in, 240–241
- Neurons
angiotensin (3–8) receptors in, 254–262
AT₁ receptors, in hypertension, 40
AT₂ receptors in, 40
- Nodose ganglion, 225–227, 228
- Non-AT₁, non-AT₂ receptors, *see* Atypical receptors
- Norepinephrine
angiotensin II and, 94, 96–97, 107
in adipose tissue, 45–46
angiotensin (1–7) and, 233
- Norepinephrine transporter, 71–78
- Obesity, genetic, 39, 41, 43–44, 45–46
- Oncogenes
fos induction by angiotensin, 61, 62, 71–78
in hypertrophy, 61
MAP kinase and, 62
mas protein receptor, 241–242
myc in AT₂ gene regulation, 223
- Osmotic stimuli, 108–109, 110, 116
- Ovaries
AT₂ receptors in, 183–187
granulosa cells, 175–182, 183–184
follicular atresia, 176, 178–179, 181, 184
- Ovulation, 186
- Oxytocin
AT₁ receptors and, 107, 108, 111
AT₂ receptors and, 203
- PAI-1, 71–72, 75–76
- Paraventricular nucleus
angiotensin (1–7) activity, 228, 232–233
AT₁ receptor distribution, 106–108
AT₂ receptor distribution, 203
in drinking response, 113–118
in stress response, 105–106, 108–112
- Paxillin, 62
- PC12 cells
AT_{1a} gene regulation in, 1–10
AT₂ receptors in, 148, 150, 181, 210
properties of, 9
- PD123177, 237
- PD123319
AT₂ subtypes and, 168, 204
specificity for AT₂, 116, 237
- Pertussis toxin, 209
- Phenobarbital, AT₁ density and, 39–40, 41, 44, 46
- Phosphatidic acid, 62
- Phosphoinositide/calcium pathway
angiotensin (3–8) receptors and, 242
AT₁ receptors and, 11, 40, 62, 217
in astrocytes, 123, 125, 126
AT₂ receptors and, 148
desensitization of calcium transients, 63, 64, 65
- Phospholipase A₂, 126–127
- Phospholipase C, 11, 62, 123, 125–126; *See also*
Phosphoinositide/calcium pathway
- Phospholipase D, 62
- Pineal gland, renin in, 96
- Pit-1 transcription factor, 18
- Pituitary, 105, 106
- Potassium currents, 148, 209, 210
- Potassium depletion, 56
- POU transcription factors, 18, 223
- Pregnancy
AT₂ down-regulation in, 150
ovarian RAS during, 183
- Pressor response, catecholamines and, 94, 97, 106, 107–108
- Pressure-overload model, 60
- Prolactin, 98, 107
- Prostaglandins
angiotensin (1–7) and, 232, 243
AT₁ receptors and
in adipose tissue, 45
in astrocytes, 123, 125–128
AT₂ receptors and, 155, 167, 232
atypical neuroblastoma receptors and, 240
- Protein kinase A, 63–64
- Protein kinase C
AT₁ coupling to, 59, 62
in AT₁ desensitization, 63–64
phosphorylation sites on AT₂, 147
- Protein phosphatase 2A (PP2A), 209–215
- Protein tyrosine phosphatase (PTPase), 31, 61, 155, 176
in adrenal cortex, 181
in COS-7 cells, 210
in neuroblastoma cells, 167, 170–172
in NG108–15 cells, 149
in PC12W cells, 148, 181, 210
T-type calcium channels and, 181
- Receptors, *see* AT₁ receptors; AT₂ receptors; Atypical receptors
- Renin, angiotensin (3–8) and, 242
- Renin-angiotensin system, *see also* Angiotensinogen
in adipose tissue, 40
in brain, 121
catecholamines and, 93–103
glucocorticoids and, 111
hypertension and, 71, 75–76, 85–86, 121
pineal, 96
drinking response and, 117
in heart, 23, 60

- Renin-angiotensin system (*cont*)
 hypertension and, 49–50, 55–57, 71, 75–76,
 85–86, 121
 kidney in, 199
 in ovary, 176, 183–185
 sodium intake and, 37
 Renin-transgenic rat, 72, 76
- Saralasin, 238
 [Sar¹,Ile⁸]-angiotensin II, 238
 Second messengers, *see* Signal transduction
 Sendai virus, 219
 Serine kinases, 63–64
 Serine/threonine phosphatases
 AT₂ receptor and, 148, 149, 176
 PP2A, 209–215
 Serotonin
 angiotensin binding and, 233
 drinking response and, 117
 SHC proteins, 62
 Shear-stress inducible transcription factor,
 19
 Signal transduction
 with angiotensin (3–8) receptors, 242
 with AT₁ receptors, 11, 40, 59–60, 62–66, 67,
 217
 in astrocytes, 123, 125, 126
c-fos in, 76
 with AT₂ receptors, 61, 148–149, 209–215,
 217, 221–222
sis inducing factor, 63
 Sodium intake
 AT₁ receptors and, 33–37
 drinking response and, 117–118
 Solitary tract, nucleus of, 93, 94
 Somatostatin, 107
 Spontaneously hypertensive rat
 AT₁ expression, 71, 72, 75–76
 brain Fos expression, 115
 Src kinases, 63
 STAT pathway, 59, 62–63, 65
 Stress responses, 105, 108–110, 111, 112
 Stroke, gerbil model for, 248
 Stroke-prone spontaneously hypertensive rat
 AT₁ expression in, 71–78
Bp3 gene in, 218
- Subfornical organ
 in DOCA-salt model, 76
 in drinking response, 113–118
 Substance P, 226, 227, 228, 232
 Supraoptic nucleus
 AT₂ receptors in, 203
 drinking response and, 113–118
 Sympathetic nervous system
 angiotensin activation of, 60, 94–97, 109–110
 angiotensin inhibition of, 226–227
 in hypertension, 50, 55
- T-type calcium channels, 148, 155, 181
 TCV-116, 50
 Testosterone, ovarian receptors and, 185
 Tetrahydroimidazopyridine antagonists, 237
 Thirst, *see* Drinking response
 Transcription factors
 for AT₁ gene, 18–20, 46
 for AT_{1a} gene, 1–10
 for AT₂ gene, 151, 163, 222–223
 MAP kinase and, 62
 STAT proteins, 62–63
 Turkey receptors, 240
 Tyrosine dephosphorylation, *see* Protein tyrosine
 phosphatase
 Tyrosine hydroxylase, 233
 Tyrosine phosphorylation
 AT_{1a} activation of, 59, 62, 67
 of AT_{1a} receptors, 63–65
- Uterus, AT₁ receptors in, 8
- Vagal reflexes, 225–226
 Vascular smooth muscle, repair of, 149, 172, 218–
 222, 237
 Vasopressin
 angiotensin (1–7) and, 242
 AT₁ receptors and, 9
 AT₂ receptors and, 203
 catecholamines and, 94, 96, 97, 106, 107–108,
 109, 111
 Viral-mediated gene transfer, 218–220
- X chromosome, AT₂ gene on, 218
Xenopus receptors, 239–240, 242